Compare KeyCorp (KEY) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
KeyCorp vs Travere Therapeutics Inc. Common Stock — how do they compare? KeyCorp trades at $19.83 (market cap $21.25B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: KeyCorp is far larger — about 4.4× Travere Therapeutics Inc. Common Stock's market cap, and KeyCorp pays a 4.12% dividend while Travere Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold KeyCorp for 66 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| KEY | TVTX | |
|---|---|---|
Market Cap | $21.25B | $4.88B |
Volume | 17,676,934 | 1,668,577 |
Sector | Financials | Health |
52-Week High | $23.99 | $67.52 |
52-Week Low | $16.78 | $26.79 |
Typical Hold Time | 66 Days | 0 Days |
Enterprise Value | $34.43B | $5.01B |
Dividend Yield | 4.12% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
KeyCorp (KEY) trades at $19.91, down 0.9% on the day, with a bearish technical outlook despite strong fundamentals. The company has beaten earnings estimates for three consecutive quarters, with Q3 2026 results pending. Analyst consensus remains strongly bullish with a $25.00 price target, representing 25% upside potential. Recent corporate developments include leadership appointments and a maintained dividend payout.
KEY presents a compelling value opportunity with attractive valuation metrics (P/E 11.64, P/B 1.23) and improving profitability (26.72% net margin). However, technical indicators signal near-term weakness, and the stock faces headwinds from interest rate sensitivity and competitive pressure on dividends. The disconnect between strong fundamentals and bearish technicals creates potential for recovery if earnings momentum continues.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About KeyCorp
With assets of over $170 billion, Ohio-based KeyCorp's bank footprint spans 16 states, but it is predominantly concentrated in its two largest markets: Ohio and New York. KeyCorp is primarily focused on serving middle-market commercial clients through a hybrid community/corporate bank model.
Read more on KEY →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
